Award11 Nov 2025, 05:01 pm
Panacea Biotec Secures US$4.75 Million Agreement with PAHO for Supply of Easyfive-TT Vaccine
AI Summary
Panacea Biotec Ltd has received an Award notification from PAHO under a Long-Term Agreement for the supply of Easyfive-TT, a Diphtheria-Tetanus-Pertussis-Hepatitis B-Haemophilus influenzae type B (DTP-HepB-Hib) Vaccine. The agreement, worth approximately US$4.75 million, is valid until December 31, 2027, with supplies scheduled for Calendar Years 2026 and 2027.
Key Highlights
- Panacea Biotec secures a US$4.75 million agreement with PAHO for the supply of Easyfive-TT Vaccine.
- The agreement is valid until December 31, 2027, with supplies scheduled for Calendar Years 2026 and 2027.
- The Easyfive-TT Vaccine is a Diphtheria-Tetanus-Pertussis-Hepatitis B-Haemophilus influenzae type B (DTP-HepB-Hib) Vaccine.
- The agreement was awarded under a Long-Term Agreement by PAHO, the Regional Office of World Health Organization.